These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 39004098)

  • 21. Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Granted Breakthrough Therapy Designation in China, 2020-2024.
    Luo X; Du X; Lv X; Yang Y; Zhang X; Huang L
    JAMA Netw Open; 2024 Oct; 7(10):e2439080. PubMed ID: 39412805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).
    Elbaz J; Haslam A; Prasad V
    Cancer Med; 2024 Apr; 13(8):e7190. PubMed ID: 38659418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.
    Lau C; Dranitsaris G
    Curr Oncol; 2022 Oct; 29(11):8031-8042. PubMed ID: 36354695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.
    Miller JE; Mello MM; Wallach JD; Gudbranson EM; Bohlig B; Ross JS; Gross CP; Bach PB
    JAMA Netw Open; 2021 May; 4(5):e217075. PubMed ID: 33950209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study.
    Boyle JM; Hegarty G; Frampton C; Harvey-Jones E; Dodkins J; Beyer K; George G; Sullivan R; Booth C; Aggarwal A
    Eur J Cancer; 2021 Sep; 155():136-144. PubMed ID: 34371443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
    Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
    JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018.
    DeMartino PC; Miljkovic MD; Prasad V
    JAMA Intern Med; 2021 Feb; 181(2):162-167. PubMed ID: 33165499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
    Benjamin DJ; Xu A; Lythgoe MP; Prasad V
    JAMA Netw Open; 2022 Mar; 5(3):e222265. PubMed ID: 35289858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.
    Gupta R; Dhruva SS; Fox ER; Ross JS
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1066-1076. PubMed ID: 28944731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Oncologic Drugs from 2008 to 2023-Differences in Approval and Access between the United States, Europe and Brazil.
    Barreto RB; Izidoro AM; Miranda MHF
    Curr Oncol; 2024 Aug; 31(8):4443-4454. PubMed ID: 39195315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.
    Lythgoe MP; Krell J; Bower M; Murphy R; Marriott J; Blagden SP; Aggarwal A; Sullivan R
    Lancet Oncol; 2023 Apr; 24(4):e150-e160. PubMed ID: 36990613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.
    Arora S; Narayan P; Osgood CL; Wedam S; Prowell TM; Gao JJ; Shah M; Krol D; Wahby S; Royce M; Ghosh S; Philip R; Ison G; Berman T; Brus C; Bloomquist EW; Fiero MH; Tang S; Pazdur R; Ibrahim A; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2022 Mar; 28(6):1072-1086. PubMed ID: 34711632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.
    Michaeli JC; Michaeli T; Trapani D; Albers S; Dannehl D; Würstlein R; Michaeli DT
    Breast Cancer; 2024 Nov; 31(6):1144-1155. PubMed ID: 39320645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology.
    Michaeli DT; Michaeli T
    Value Health; 2023 Nov; 26(11):1590-1600. PubMed ID: 37516196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
    Meyers DE; Jenei K; Chisamore TM; Gyawali B
    JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
    McCormick JI; Berescu LD; Tadros N
    Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment.
    Ho C; Lim HJ; Regier DA
    Curr Oncol; 2022 Jan; 29(2):402-410. PubMed ID: 35200536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.
    Michaeli DT; Michaeli T
    J Clin Oncol; 2022 Dec; 40(35):4095-4106. PubMed ID: 35921606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.